Short Interest in TC Biopharm (Holdings) Plc (NASDAQ:TCBP) Declines By 84.2%

TC Biopharm (Holdings) Plc (NASDAQ:TCBP) saw a significant decrease in short interest in July. As of July 31st, there was short interest totalling 5,200 shares, a decrease of 84.2% from the July 15th total of 32,900 shares. Based on an average trading volume of 18,500 shares, the short-interest ratio is presently 0.3 days.

TC Biopharm Stock Performance

Shares of TC Biopharm stock traded down $0.05 during trading hours on Monday, hitting $3.96. The company’s stock had a trading volume of 53,755 shares, compared to its average volume of 232,076. The business has a fifty day moving average of $8.25 and a 200 day moving average of $11.46. TC Biopharm has a 1-year low of $3.28 and a 1-year high of $138.00. The company has a debt-to-equity ratio of 1.31, a current ratio of 0.88 and a quick ratio of 0.88.

TC Biopharm (NASDAQ:TCBP) last released its quarterly earnings results on Wednesday, May 15th. The company reported ($28.00) earnings per share for the quarter.

TC Biopharm Company Profile

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers.